Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Status:
Completed
Trial end date:
2018-05-27
Target enrollment:
Participant gender:
Summary
Multicenter, open label, non-randomized phase 2 trial to evaluate the efficacy and safety of
nab-paclitaxel in the neoadjuvant treatment of ER positive human epidermal growth factor
receptor 2 (HER2) negative patients amenable to receive neoadjuvant chemotherapy.